The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical features associated with an exceptional response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC).
 
Yunan Nie
No Relationships to Disclose
 
Anna Wurtz
No Relationships to Disclose
 
Fangyong Li
Consulting or Advisory Role - Yiviva
 
Kurt Schalper
Consulting or Advisory Role - Abbvie; Agenus; AstraZeneca; Bristol Myers Squibb; CDR-Life; Clinica Alemana; DynamiCure Biotechnology; Indaptus; Janssen; Menarini; Merus; Molecular Templates; OnCusp Therapeutics; Parthenon Therapeutics; Picture Health; Roche; Sanofi; Takeda
Speakers' Bureau - Forefront Collaborative; HMP; Merck; Peerview; PeerView; Sanofi
Research Funding - Akoya Biosciences (Inst); AstraZeneca; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Lilly; Merck; Ribon Therapeutics; Roche (Inst); Takeda; Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Patent No. 16/464,010 (PREDICTION OF RESPONSE TO IMMUNE-MODULATORY THERAPIES)
Expert Testimony - AstraZeneca
 
Emily Duffield
Honoraria - Takeda
 
Elin Rowen
No Relationships to Disclose
 
Heather Gerrish
No Relationships to Disclose
 
Anne Chiang
Consulting or Advisory Role - Abbvie; Abbvie; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BMS; Boehringer Ingelheim; Catalyst Pharmaceuticals; Daichi; Flatiron Health; Fosun Pharma; Genentech; Genentech; Genentech; Genentech/Roche; Janssen Oncology; Jazz Pharmaceuticals; Jazz Pharmaceuticals; regeneron; Sanofi/Regeneron; Zai Lab
Research Funding - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Millennium; OncoMed; Onyx; Stem CentRx; Zai Lab
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech/Roche
 
Sarah Goldberg
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Daiichi Sankyo; Janssen; Lilly; Merck; Regeneron; Summit Therapeutics; Synthekine
Research Funding - Adela; Agenus (Inst); Amgen (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genentech (Inst); Merck (Inst); Mirati Therapeutics; ORIC Pharmaceuticals (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst); Vitrak (Inst)
 
Frederick Wilson
Consulting or Advisory Role - Loxo
Research Funding - Agios
 
So Yeon Kim
Consulting or Advisory Role - Amgen; Genentech; Revolution Medicines
Research Funding - AstraZeneca (Inst); Bioinvent (Inst); Boehringer Ingelheim (Inst); Bridgebio (Inst); Bristol Myers Squibb Foundation (Inst); DynamiCure Biotechnology (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); Loxo/Lilly (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst)
 
Michael Grant
Honoraria - Daiichi Sankyo/Astra Zeneca
Consulting or Advisory Role - Regeneron
Research Funding - Adela (Inst)
 
Kert Sabbath
No Relationships to Disclose
 
Ashita Talsania
No Relationships to Disclose
 
Johanna Lasala
Stock and Other Ownership Interests - Amgen; Biogen; Bristol-Myers Squibb (I); crispr therapeutics (I); Gilead Sciences (I); Mannkind (I); Roche (I); Tiziana Life Sciences (I); Viking Therapeutics (I); Xilio Therapeutics
 
Armand Russo
No Relationships to Disclose
 
Katerina Politi
Stock and Other Ownership Interests - Reveal Therapeutics, Inc
Consulting or Advisory Role - AstraZeneca; Janssen; Pfizer; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); D2G Oncology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent licensed by MSKCC to Molecular MD for T790M testing
Travel, Accommodations, Expenses - AstraZeneca; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Lung Cancer Research Foundation
 
Roy Herbst
Leadership - American Association for Cancer Research; Friends of Cancer Research; IASLC; Immunocore; Junshi Pharmaceuticals; Society for Immunotherapy of Cancer; SWOG
Stock and Other Ownership Interests - Bolt Biotherapeutics; Checkpoint Therapeutics; Immunocore; Normunity
Consulting or Advisory Role - Abbvie; Amgen; ArriVent Biopharma; AstraZeneca; Bristol-Myers Squibb; Candel Therapeutics; Catalym; Checkpoint Therapeutics; Cybrexa Therapeutics; Genentech/Roche; Gilead/Forty Seven; I-Mab; Janssen; Junshi Pharmaceuticals; Lilly; Mediflix; Merck; NEUVOGEN; NextCure; Normunity; Novartis; Pfizer; Regeneron; Roche; Sanofi
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
Travel, Accommodations, Expenses - American Cancer Society; IASLC; SWOG
 
Scott Gettinger
Research Funding - ARIAD/Takeda (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); NextCure (Inst)